Our Company
Presentation
Management Team
Board of directors
Scientific Advisory Board
Contact
Products
Tedopi®
OSE-279
Lusvertikimab (OSE-127)
Pegrizeprument (FR104)
BI 770371
ABBV-230
CLEC-1
Research & Development
Scientific publications
Investors
Press Releases
Letter to Shareholders
Newsletters
Q & A
Financial documents
General Shareholders’ meetings
Regulated information
Partnerships
Pharma partnerships
Clinical partnerships
Academic and public Partnerships
News
Our videos
Agenda
Press Releases
Contact
en
fr
Retour aux actualités
Kepler Cheuvreux: OSE Immunotherapeutics unveils its 26-28 strategic plan
09 December 2025